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TCT-303
Optimal interventional strategy in patients underwent plasmonicphotothermal
therapy of atherosclerosis: subanalysis of NANOM-FIM trial
Alexander N. Kharlamov1
1Erasmus University Medical Center, Rotterdam, South Holland
Background: Our previous studies documented acceptable efﬁcacy of plasmonic-
photothermal therapy (PPTT) with plaque burden reduction up to 79.4 mm3 and 60.3
mm3 respectively. Stenting or balloon angioplasty were utilized in order to prepare
target lesions that requires a special analysis.
Methods: This is a retrospective subanalysis of the 1-year imaging and 5-year clinical
outcomes in three subsets (n¼180) of NANOM-FIM trial (NCT01270139). At the ﬁrst
subset patients underwent stenting with XIENCE V stent proximal to the site of nano-
intervention (n¼13). Subjects in the second subset were undergone drug-coated
balloon pre-dilatation with further nano-technique (n¼20). Lesions in patients of the
third subset were not prepared for the nano-approach (n¼147).
Results: The reduction of the TAV at 12-month follow-up was 40.9%/36.6%/42.6%,
and 45.0%/46.1%/40.9% (p<0.05) in three subsets of Nano and Ferro groups
respectively. A 5-year MACE-free survival achieved 39/60 (65.0%), 32/60 (53.3%),
and 34/60 (56.7%) in the intention-to-treat population in groups respectively
(p<0.05). Nano-intervention (HR 1.00 vs 0.67, p¼0.03) in subset with stenting
proximal to the target lesion was indicated as independent predictor of MACE in Nano
group. Hypertension (p<0.01), alcohol abuse (p¼0.04), smoking (p¼0.05), heart
failure (p¼0.05) and previous or simultaneous PCI (p<0.01) were independent
predictors of MACE in stenting control group if compare with subsets of Nano and
Ferro groups.
Conclusions: The “no preparation” strategy demonstrates an optimal proﬁle of efﬁ-
cacy and safety at the long-term follow-up in patients underwent PPTT of athero-
sclerosis. The stenting proximal to nano-intervention shows superiority to the drug-
coated balloon pre-dilatation of the target lesion.
TCT-304
Retrospective analysis of long-term outcomes in NANOM-FIM trial: safety of
plasmonicphotothermal therapy of atherosclerosis
Alexander N. Kharlamov1
1Erasmus University Medical Center, Rotterdam, South Holland
Background: Our previous bench studies PLASMONICS and NANOM First-in-Man
(FIM) trial documented total atheroma volume (TAV) reduction up to unprecedented
79.4 and 60.3 mm3 respectively. But the safety options in nanomedicine raise an issue
of the optimal niche of these technologies at the real-world clinical practice.
Methods: This is a retrospective analysis of the 5-year long-term clinical outcomes at
the intention-to-treat population (n¼180) of NANOM-FIM trial (NCT01270139). The
primary outcome was a composite of end-point of MACE-free survival, MACE,
cardiac death, TLR (target lesion revascularization) and TVR (target vessel
revascularization).
Results: Mortality (6 vs 9 vs 10 cases of cardiac death in groups respectively,
p<0.05), MACE (14.3% of nano group vs 22.9% in stenting control, p¼0.04), late
thrombosis (2 vs 4 vs 6 cases in groups respectively, p<0.05) and TLR (3.8 vs 5.7% in
nano and stent group respectively, p¼0.04) were signiﬁcantly higher in ferro group
and stent control at 60-month follow-up, but the difference in the proportion of
MACE-free survival and TVR incidence when compared between groups did not
reach statistical signiﬁcance (p¼0.33). Diabetes (p¼0.03), hypertension (p¼0.05),
previous or simultaneous PCI (p¼0.048) and heart failure (p¼0.04) were conﬁrmed as
strong independent predictors of cardiac death with high rate of mortality and late
thrombosis in patients underwent stenting.
Conclusions: NANOM-FIM trial demonstrates high safety of the selected nano-
technologies with better rate of mortality, MACE and TLR at the long-term follow-up
if compare with conventional implantation of the second generation stent XIENCE V.B98 JACC Vol 62/18/Suppl B j October 27–NovemTCT-305
SeQuent Please Paclitaxel-Coated Balloon Angioplasty For De Novo Coronary
Lesions: A Long-Term Follow-Up Study
Javier Benezet1, Ignacio Sanchez-Perez1, Fernando Lozano1, Natalia Pinilla1,
Felipe Higuera1, Yasser Hessein1
1Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
Background: Paclitaxel-coated balloons (PCB) have been demonstrated to be
successful for the treatment of in-stent restenosis; however, their role in the treatment
of de novo lesions is unclear. This study aimed to evaluate the long-term safety and
efﬁcacy of the second-generation SeQuent Please PCB for the treatment of de novo
coronary lesions.
Methods: Between May 2009 and April 2011, all consecutive patients with de novo
coronary lesions treated with the SeQuent Please PCB at our institution were
prospectively included. Bare-metal stent (BMS) were implanted if the result after PCB
therapy alone was not satisfactory because of recoil, residual stenosis or dissections.
Patients were followed up for 24 months by clinical observation. The primary
endpoint was the clinically driven target lesion revascularization (TLR) rate at 24
months. The secondary endpoint was the rate of major adverse cardiac events (MACE:
deﬁned as a composite of cardiac death, myocardial infarction, and TLR) at 24
months.
Results: 53 patients with 56 lesions were included. Mean age was 66.111.9 years.
62.5 % were male and 50 % were diabetics. The majority of patients presented with
unstable angina (44.6%). The target lesion was mainly located in the left anterior
descending coronary artery (60.7%) and 23.2 % were bifurcation lesions. The mean
reference vessel diameter was 2.40.4 mm and the mean target lesion length was
18.16.2 mm.Procedural success was 98.2%. Coronary dissection occurred in 7
patients (12.5 %) and no vessel thrombosis was documented. Additional BMS was
implanted in 14 target lesions (25 %). Follow-up rate was 94.3 %. The TLR rate at 24
months was 5.4 %. The MACE rate at 24 months was 8.9 %, with 1.8 % cardiac death
and 3.6 % myocardial infarction. Baseline and procedural data for patients with PCBs
versus PCBs plus BMS did not differ. The TLR and MACE rates did not differ
between PCB angioplasty with and without additional BMS implantation (TLR: 0%
vs.7.1%, p¼0.56; MACE: 7.1 % vs. 9.5 %, p ¼ 0.78).
Conclusions: Treatment of de novo coronary lesions with the second-generation
SeQuent Please PCB provides good clinical outcomes demonstrated by the low TLR
rate and low MACE rates at long-term follow-up.
TCT-306
Prevalence Of Myocardial Bridging In Patients With Takotsubo
Cardiomyopathy
Chris Cianci1, Gautam R. Patankar1, Jeffrey M. Schussler1
1Baylor University Medical Center, Dallas, TX
Background: Takotsubo cardiomyopathy, also known as broken heart syndrome,
apical ballooning syndrome, and stress-induced cardiomyopathy, is an increasingly
recognized entity characterized by transient left ventricular systolic dysfunction.
While the clinical presentation often mimicks acute coronary syndrome, the angio-
gram typically lacks obstructive coronary lesions. The pathogenesis of takotsubo
cardiomyopathy is not well understood and the angiographic characteristics of these
patients are not well described.
Methods: We reviewed the angiograms of 87 Takotsubo cardiomypathy patients
referred for cardiac catheterization at Baylor University Medical Center from 2005 to
2013. Myocardial bridging was diagnosed if a dynamic compression of a coronary
artery was observed during systole. Severity of bridging was assessed by the angio-
graphic degree of systolic compression and as follows: Grade 1 (less than 50% nar-
rowing), Grade 2 (50 to 75% narrowing), Grade 3 (more than 75% narrowing).
Results: Myocardial bridging was observed in 83 of the 87 patients with Takotsubo
cardiomyopathy (95%). 79 of the 83 patients had Grade 1 bridging (95%). There were
2 patients that had Grade 2 bridging (2.5%) and 2 patients with Grade 3 bridging
(2.5%). The LAD was the most common coronary artery involved.
Conclusions: Myocardial bridging is more common in patients with Takotsubo
cardiomyopathy than in the general population. This may have some relevance with
regard to the pathophysiology.
TCT-307
Frequency and Impact of Failure to Cannulate the Left Internal Mammary
Artery: Results of the SLIME1 (Selective Left Internal Mammary Evaluation)
Trial
Evin Yucel1, Brian J. McEniry1, Deepak Thatai2, Brian J. Corbett1, Zoltan Turi1
1Cooper Medical School of Rowan University, Camden, NJ, 2Cambridge Health
Alliance, Everett, MA
Background: The left internal mammary artery (LIMA) is used in over 90% of
coronary bypass surgeries. Although acknowledged to be technically challenging, the
failure rate of selective LIMA injection and its impact on ability to diagnose disease
severity have not been reported.
Methods: Patients undergoing LIMA injection between 3/2007 and 4/2009 were
screened. Those without prior CABG were excluded. Angiograms were quantitatively
analyzed for distance of catheter tip from LIMA origin and classiﬁed as:ber 1, 2013 j TCT Abstracts/POSTER/Miscellaneous Coronary Topics
